Summary & Overview
CPT 84153: Total Prostate Specific Antigen (PSA) Test
CPT code 84153 represents the laboratory measurement of total prostate specific antigen (PSA) in serum or plasma. PSA testing is a widely used tool for clinician evaluation of prostate health, including population-level screening discussions and individual patient monitoring for prostate cancer progression or treatment response. As a common clinical chemistry assay, CPT code 84153 is relevant across hospital, outpatient, and independent laboratory settings and factors into both preventive care pathways and oncology monitoring protocols.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for PSA testing, national reimbursement and utilization benchmarks where available, and policy considerations affecting laboratory billing and reporting for this code. The publication also summarizes payer coverage trends, denial drivers, and common documentation points that influence claim adjudication for PSA testing. The content is intended to help billing managers, laboratory directors, and policy analysts understand how CPT code 84153 is used in clinical practice and processed by major payers at a national level.
Billing Code Overview
CPT code 84153 describes a laboratory test measuring total prostate specific antigen (PSA) in blood (typically serum or plasma). PSA is a protein produced by the prostate gland; clinicians use measured PSA levels to screen for prostate cancer and to monitor disease progression or treatment response in patients with known prostate conditions.
-
Service type: Clinical laboratory testing of a blood specimen using automated laboratory analyzers
-
Typical site of service: Clinical laboratory, hospital laboratory, or outpatient laboratory draw site
Clinical & Coding Specifications
Clinical Context
A 62-year-old male presents to his primary care physician for routine cancer screening and reports intermittent urinary hesitancy. The clinician orders a serum total prostate specific antigen test (84153) to screen for prostate malignancy and to establish a baseline prior to shared decision-making about further evaluation. Blood is collected in the outpatient clinic phlebotomy station and sent to the hospital core laboratory. The laboratory analyst performs 84153 on a clinical chemistry analyzer and posts the numeric PSA value to the electronic health record. The primary care clinician reviews the result and documents interpretation and any follow-up plan, such as repeat PSA testing, urology referral, or additional diagnostic work-up depending on PSA level and clinical context.
Common workflow steps:
-
Patient check-in and consent for routine labs.
-
Phlebotomy and specimen labeling/transport to the clinical laboratory.
-
Laboratory processing and performance of
84153using validated immunoassay instrumentation. -
Result verification by laboratory personnel and release to the ordering provider.
-
Provider review and clinical decision-making (repeat testing interval, referral, or additional diagnostics).